Cargando…

From HIV protein sequences to viral fitness landscapes: a new paradigm for in silico vaccine design

Detalles Bibliográficos
Autores principales:	Ferguson, AL, Chakraborty, AK
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441508/ http://dx.doi.org/10.1186/1742-4690-9-S2-P331

Ejemplares similares

P17-14. Fitness-informed HIV-1 Gag-p24 vaccine design
por: Rolland, MM, et al.
Publicado: (2009)

Antiretroviral therapy targeting HIV-1 viral infectivity factor; in silico approach
por: Karau, Muriira G, et al.
Publicado: (2009)

In-silico designing of acyclic nucleoside phosphonates and their anti-HIV potential
por: Yadav, Dipti, et al.
Publicado: (2012)

P09-09. Impact of immune-driven sequence variation in HIV-1 subtype C Gag-Protease on viral fitness and disease progression
por: Wright, JK, et al.
Publicado: (2009)

P12-09. Immune responses in controlled and uncontrolled HIV infection to a designed HIV immunogen sequence focused on conserved regions of the viral genome
por: Mothe, B, et al.
Publicado: (2009)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
por: Lynch, RM, et al.
Publicado: (2012)

Design and development of a new lentiviral based anti-HIV therapeutic vaccine
por: Rodriguez, M, et al.
Publicado: (2012)

Improved T1 fitting with the MOLLI sequence
por: Cooper, Mitchell A, et al.
Publicado: (2013)

P17-26. Effective design of T-cell driven vaccines applied to the GAIA HIV vaccine: advances in vaccine design based on current preclinical success
por: De Groot, AS, et al.
Publicado: (2009)

Immunogenic selection of HIV-1 MPER epitopes for improved vaccine design
por: Wieczorek, L, et al.
Publicado: (2012)

Virtual screening and in silico design of novel inhibitors of bacterial lectins
por: Alán, Jan, et al.
Publicado: (2012)

P14-04. HIV-SELECTEST EIA and rapid test: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies
por: Khurana, S, et al.
Publicado: (2009)

HEXploring of the HIV-1 genome allows landscaping of new potential splicing regulatory elements
por: Erkelenz, Steffen, et al.
Publicado: (2013)

Vaccination with dendritic cells loaded with HIV-1 lipopeptides elicits broad T cell immunity and control of viral load in HIV infected patients
por: Levy, Y, et al.
Publicado: (2012)

P19-39. Vaccibodies: a novel vaccine strategy for HIV that target viral antigens to APC
por: Øynebråten, I, et al.
Publicado: (2009)

In silico prediction of the neutralization range of human anti-HIV monoclonal antibodies
por: Shmelkov, E, et al.
Publicado: (2012)

L-Systems: a mathematical paradigm for designing full length human genes and genomes
por: Goswami, Arunava, et al.
Publicado: (2010)

Modelling the neuropathological consequences of HIV vaccines that confer partial protection
por: Ferguson, D, et al.
Publicado: (2012)

HIV-1 natural viral suppressors: control of viral replication in the absence of therapy
por: Sajadi, Mohammad
Publicado: (2006)

In silico analysis of mobile elements-derived sequences in schizophrenia-related genes
por: Osimo, Emanuele F, et al.
Publicado: (2009)

HbAHP-25, a peptide designed in silico, exhibits potent anti-HIV activity in vitro
por: Bashir, Tahir, et al.
Publicado: (2014)

DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials
por: Morgan, C, et al.
Publicado: (2012)

Influence of hormones and HIV infection on viral transport
por: Stieh, DJ, et al.
Publicado: (2012)

Chronic viral hepatitis in HIV infected patients
por: Niculescu, Irina, et al.
Publicado: (2013)

P19-45. Development of a therapeutic HIV vaccine comprised of autologous dendritic cells loaded with a mixture of lipopeptide HIV antigens
por: Cobb, AJ, et al.
Publicado: (2009)

Fitting a vaccine into the HIV prevention landscape
por: Fauci, Anthony S., et al.
Publicado: (2021)

P19-28. The V3 region of HIV-1: from NMR to vaccine design
por: Moseri, A, et al.
Publicado: (2009)

Immunoglobulins concentration in HIV-infected patients' with viral hepatitis, candidiasis and herpes simplex viral infection
por: Sargsyants, Narina, et al.
Publicado: (2012)

P20-01. HIV-1 genetic diversity among HIV drug naive populations of Nairobi, Kenya
por: Nyamache, AK, et al.
Publicado: (2009)

Co-infection, super-infection and viral interference in HIV
por: Remion, Azaria, et al.
Publicado: (2013)

New HIV peptide-based immunoassay resolves vaccine-induced seropositivity in HIV vaccine (Phase III) trial participants
por: Penezina, O, et al.
Publicado: (2012)

Effect of HIV on production of anti-viral factors by HIV-specific CD4+ T cells
por: Hioe, Catarina, et al.
Publicado: (2006)

Design of multi-target activity landscapes that capture hierarchical activity cliff distributions
por: Dimova, Dilyana, et al.
Publicado: (2012)

The recognition of HIV-1 consensus group M Gag and Nef peptide reagents in mono- and multi-clade epidemics: implications for HIV vaccine design
por: Zembe, L, et al.
Publicado: (2012)

Rationally designed HIV envelope glycoproteins delivered in a novel adjuvant elicited more broadly reactive antigen-specific antibody responses
por: Dey, AK, et al.
Publicado: (2012)

Ventilator associated complications: observing implications of a new surveillance paradigm
por: Yuan, M, et al.
Publicado: (2015)

HIV viral load assessment in multiple sanctuaries – case presentation
por: Streinu-Cercel, Anca, et al.
Publicado: (2014)

Out-of-bed extubation: changing paradigms
por: Dexheimer Neto, F, et al.
Publicado: (2012)

Antigenic mimicry of mammalian oligomannose by a naturally occurring bacterial oligosaccharide and its implications for HIV vaccine design
por: De Castro, C, et al.
Publicado: (2012)

Breadth or conservation score (CS): which is more important for HIV-1 T cell based vaccine immunogen design?
por: Kunwar, P, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_pdjoedv1a95s6g1sjro4jcon4l